Healthy dietary patterns to reduce obesity-related metabolic disease: polyphenol-microbiome interactions unifying health effects across geography

Diotallevi, Camilla; Fava, Francesca; Gobbetti, Marco; Tuohy, Kieran

doi:10.1097/mco.0000000000000697

Cited by 33 publications

(15 citation statements)

References 62 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The diet type has an important role in the configuration of the gut microbiota. For example, the Western diet induces microbiome changes related to intestinal integrity, inflammation and the resolution of inflammation, storage of energy, thermogenesis and homeostasis of lipids, and the metabolism of glucose 9 . In terms of quantity, bacteria are the most abundant microorganisms in the intestinal microbiota.…”

Section: Introductionmentioning

confidence: 99%

The intestinal mycobiota and its relationship with overweight, obesity and nutritional aspects

García‐Gamboa

Kirchmayr

Gradilla‐Hernández

et al. 2021

J Human Nutrition Diet

View full text Add to dashboard Cite

Background The fungal community of the gastrointestinal tract has recently become of interest, and knowledge of its relationship with the development of obesity is scarce. The present study aimed to evaluate the cultivable fungal fraction from the microbiota and to analyze its relationship with obesity. Methods Samples were taken from 99 participants with normal weight, overweight and obesity (n = 31, 34 and 34, respectively) and were cultivated in selective medium, and the cultivable yeasts were identified by matrix‐assisted laser desorption/ionization time‐of‐flight mass spectrometry. Anthropometric and biochemical measures were also evaluated. Results Eutrophic, overweight and obese groups presented concentrations of 1.6, 2.16 and 2.19 log10 colony‐forming units g–1 yeast, respectively. Ascomycota and Basidiomycota were the two identified phyla. At the genus level, Candida spp. showed a relatively high prevalence, and 10 different species were detected: Candida glabrata, Candida orthopsilosis, Candida lambica, Candida kefyr, Candida albicans, Candida krusei, Candida valida, Candida parapsilosis, Candida utilis and Candida humilis (with relative abundances of 71.72%, 5.05%, 21.21%, 6.06%, 29.29%, 27.27%, 8.08%, 16.16%, 1.01% and 2.02%, respectively). Conclusions The obese group presented a higher prevalence of Candida albicans. Furthermore, Candida albicans, Candida kefyr and Rhodotorula mucilaginosa showed a high positive correlation with obesity, weight gain and fat mass and showed a negative correlation with high‐density lipoprotein and lean mass, parameters related to weight loss.

show abstract

Section: Introductionmentioning

confidence: 99%

The intestinal mycobiota and its relationship with overweight, obesity and nutritional aspects

García‐Gamboa

Kirchmayr

Gradilla‐Hernández

et al. 2021

J Human Nutrition Diet

View full text Add to dashboard Cite

show abstract

“…Furthermore, modulation of BAs by diet may be a promising treatment for CVDs risk factors [ 499 ]. Polyphenol- or polyphenol-rich foods increase the metabolic output of BAs and beneficial bacteria such as Bifidobacterium, Lactobacillus, Akkermansia, Bacteroides, and Eubacterium [ 500 ]. In addition, dietary fiber supplementation could also increase fecal acetate and reduce fecal cholate, deoxycholate and total BAs contents to cause weight loss [ 431 ].…”

Section: Promising Therapy Of Targeting the Gut Microbiota In Cvdsmentioning

confidence: 99%

The role of the gut microbiota in health and cardiovascular diseases

Wang

Zhang

et al. 2022

Mol Biomed

View full text Add to dashboard Cite

The gut microbiota is critical to human health, such as digesting nutrients, forming the intestinal epithelial barrier, regulating immune function, producing vitamins and hormones, and producing metabolites to interact with the host. Meanwhile, increasing evidence indicates that the gut microbiota has a strong correlation with the occurrence, progression and treatment of cardiovascular diseases (CVDs). In patients with CVDs and corresponding risk factors, the composition and ratio of gut microbiota have significant differences compared with their healthy counterparts. Therefore, gut microbiota dysbiosis, gut microbiota-generated metabolites, and the related signaling pathway may serve as explanations for some of the mechanisms about the occurrence and development of CVDs. Several studies have also demonstrated that many traditional and latest therapeutic treatments of CVDs are associated with the gut microbiota and its generated metabolites and related signaling pathways. Given that information, we summarized the latest advances in the current research regarding the effect of gut microbiota on health, the main cardiovascular risk factors, and CVDs, highlighted the roles and mechanisms of several metabolites, and introduced corresponding promising treatments for CVDs regarding the gut microbiota. Therefore, this review mainly focuses on exploring the role of gut microbiota related metabolites and their therapeutic potential in CVDs, which may eventually provide better solutions in the development of therapeutic treatment as well as the prevention of CVDs.

show abstract

“…Polyphenols are a class of plant-derived macromolecules[ 87 ]. Approximately 90%–95% of dietary polyphenols are poorly absorbed and are partially processed by the gut microbiota[ 88 ]. Fermentation of polyphenols by the gut microbiota results in the production of bioactive metabolites that can affect host physiology.…”

Section: Mucosal Homeostasis In Obesitymentioning

confidence: 99%

Gut microbiota-derived metabolites as key mucosal barrier modulators in obesity

Wei¹,

Zheng²,

Wang³

2021

WJG

View full text Add to dashboard Cite

A significant breakthrough in the field of obesity research was the demonstration that an obese phenotype could be manipulated by modulating the gut microbiota. An important next step is to elucidate a human-relevant “map’’ of microbiota-host interactions that regulate the metabolic health of the host. An improved understanding of this crosstalk is a prerequisite for optimizing therapeutic strategies to combat obesity. Intestinal mucosal barrier dysfunction is an important contributor to metabolic diseases and has also been found to be involved in a variety of other chronic inflammatory conditions, including cancer, neurodegeneration, and aging. The mechanistic basis for intestinal barrier dysfunction accompanying metabolic disorders remains poorly understood. Understanding the molecular and cellular modulators of intestinal barrier function will help devise improved strategies to counteract the detrimental systemic consequences of gut barrier breakage. Changes in the composition and function of the gut microbiota, i.e. , dysbiosis, are thought to drive obesity-related pathogenesis and may be one of the most important drivers of mucosal barrier dysfunction. Many effects of the microbiota on the host are mediated by microbiota-derived metabolites. In this review, we focus on several relatively well-studied microbial metabolites that can influence intestinal mucosal homeostasis and discuss how they might affect metabolic diseases. The design and use of microbes and their metabolites that are locally active in the gut without systemic side effects are promising novel and safe therapeutic modalities for metabolic diseases.

show abstract

Healthy dietary patterns to reduce obesity-related metabolic disease: polyphenol-microbiome interactions unifying health effects across geography

Cited by 33 publications

References 62 publications

The intestinal mycobiota and its relationship with overweight, obesity and nutritional aspects

The intestinal mycobiota and its relationship with overweight, obesity and nutritional aspects

The role of the gut microbiota in health and cardiovascular diseases

Gut microbiota-derived metabolites as key mucosal barrier modulators in obesity

Contact Info

Product

Resources

About